Arcellx Inc Total Liabilities
Arcellx Inc total liabilities. Based on the latest financial reports, Arcellx Inc (ACLX) has total liabilities worth $201.64 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ACLX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Arcellx Inc (2018–2025)
Total liabilities of Arcellx Inc from 2018 to 2025. This chart illustrates how Arcellx Inc's total liabilities have evolved over time, based on quarterly financial data. Check Arcellx Inc (ACLX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Arcellx Inc Competitors by Total Liabilities
The table below lists competitors of Arcellx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hongfa Technology Co Ltd
SHG:600885
|
China | CN¥7.02 Billion |
|
NINGBO SHANSHAN GDR/A
F:OJ8
|
Germany | €22.34 Billion |
|
Gaztransport & Technigaz SAS
PA:GTT
|
France | €353.99 Million |
|
Bank of Maharashtra
NSE:MAHABANK
|
India | Rs3.94 Trillion |
|
Hyundai Heavy Industries Holdings Co Ltd
KO:267250
|
Korea | ₩53.43 Trillion |
|
Sibanye Stillwater Limited
F:47VS
|
Germany | €105.57 Billion |
|
Shenzhen Sunway Communication
SHE:300136
|
China | CN¥6.11 Billion |
|
Lotes Co Ltd
TW:3533
|
Taiwan | NT$10.66 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Arcellx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Arcellx Inc's balance sheet.
Liquidity & Leverage Metrics
Arcellx Inc Total Liabilities Ratios Explained
Arcellx Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcellx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcellx Inc (2018–2025)
The table below shows the annual total liabilities of Arcellx Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $201.64 Million | -21.40% |
| 2024-12-31 | $256.54 Million | -24.49% |
| 2023-12-31 | $339.75 Million | +212.09% |
| 2022-12-31 | $108.86 Million | -56.51% |
| 2021-12-31 | $250.30 Million | +3399.19% |
| 2020-12-31 | $7.15 Million | -90.63% |
| 2019-12-31 | $76.33 Million | +4102.97% |
| 2018-12-31 | $1.82 Million | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more